Mangalam Drugs & Organics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Mangalam Drugs & Organics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 17.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Additional Considerations Required While Assessing Mangalam Drugs & Organics' (NSE:MANGALAM) Strong Earnings
Nov 22
Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues Are Not Doing Enough For Some Investors
Aug 13A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
May 23Little Excitement Around Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Revenues As Shares Take 25% Pounding
Mar 28Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Shares Lagging The Industry But So Is The Business
Feb 07Estimating The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Oct 20Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Mar 29These 4 Measures Indicate That Mangalam Drugs & Organics (NSE:MANGALAM) Is Using Debt Extensively
May 31A Look At The Fair Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Apr 06We Think Mangalam Drugs & Organics (NSE:MANGALAM) Is Taking Some Risk With Its Debt
Jan 03Here's Why Mangalam Drugs & Organics (NSE:MANGALAM) Can Manage Its Debt Responsibly
May 23Is Mangalam Drugs & Organics (NSE:MANGALAM) A Risky Investment?
Jan 04Do Its Financials Have Any Role To Play In Driving Mangalam Drugs & Organics Limited's (NSE:MANGALAM) Stock Up Recently?
Nov 12
A Look At The Intrinsic Value Of Mangalam Drugs & Organics Limited (NSE:MANGALAM)
Sep 20Does Mangalam Drugs & Organics's (NSE:MANGALAM) Statutory Profit Adequately Reflect Its Underlying Profit?
Aug 05We Think Mangalam Drugs & Organics (NSE:MANGALAM) Can Stay On Top Of Its Debt
Jul 01In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mangalam Drugs & Organics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 3,552 | 94 | N/A | N/A | N/A |
| 6/30/2024 | 3,568 | 31 | N/A | N/A | N/A |
| 3/31/2024 | 3,674 | -91 | -79 | 39 | N/A |
| 12/31/2023 | 3,595 | -170 | N/A | N/A | N/A |
| 9/30/2023 | 3,245 | -171 | N/A | N/A | N/A |
| 6/30/2023 | 3,477 | -113 | N/A | N/A | N/A |
| 3/31/2023 | 3,702 | 13 | 116 | 395 | N/A |
| 12/31/2022 | 4,109 | 123 | N/A | N/A | N/A |
| 9/30/2022 | 4,426 | 159 | 44 | 279 | N/A |
| 6/30/2022 | 4,505 | 182 | N/A | N/A | N/A |
| 3/31/2022 | 4,509 | 197 | -20 | 257 | N/A |
| 12/31/2021 | 4,185 | 151 | N/A | N/A | N/A |
| 9/30/2021 | 4,058 | 175 | -73 | 315 | N/A |
| 6/30/2021 | 3,813 | 241 | N/A | N/A | N/A |
| 3/31/2021 | 3,800 | 280 | -39 | 275 | N/A |
| 12/31/2020 | 3,774 | 309 | N/A | N/A | N/A |
| 9/30/2020 | 3,507 | 261 | 221 | 361 | N/A |
| 6/30/2020 | 3,210 | 158 | N/A | N/A | N/A |
| 3/31/2020 | 2,824 | 83 | 236 | 305 | N/A |
| 12/31/2019 | 2,423 | -28 | N/A | N/A | N/A |
| 9/30/2019 | 2,290 | -89 | N/A | N/A | N/A |
| 6/30/2019 | 2,336 | -80 | N/A | N/A | N/A |
| 3/31/2019 | 2,276 | -80 | 124 | 217 | N/A |
| 12/31/2018 | 2,467 | 10 | N/A | N/A | N/A |
| 9/30/2018 | 2,720 | 114 | N/A | N/A | N/A |
| 6/30/2018 | 2,833 | 164 | N/A | N/A | N/A |
| 3/31/2018 | 2,794 | 199 | N/A | 246 | N/A |
| 12/31/2017 | 2,904 | 247 | N/A | N/A | N/A |
| 9/30/2017 | 2,983 | 248 | N/A | N/A | N/A |
| 6/30/2017 | 3,044 | 233 | N/A | N/A | N/A |
| 3/31/2017 | 3,029 | 223 | N/A | 428 | N/A |
| 12/31/2016 | 2,906 | 227 | N/A | N/A | N/A |
| 9/30/2016 | 2,943 | 203 | N/A | N/A | N/A |
| 6/30/2016 | 2,919 | 181 | N/A | N/A | N/A |
| 3/31/2016 | 2,952 | 160 | N/A | 218 | N/A |
| 12/31/2015 | 3,001 | 140 | N/A | N/A | N/A |
| 9/30/2015 | 2,807 | 110 | N/A | N/A | N/A |
| 6/30/2015 | 2,516 | 101 | N/A | N/A | N/A |
| 3/31/2015 | 2,207 | 61 | N/A | 140 | N/A |
| 12/31/2014 | 1,783 | 65 | N/A | N/A | N/A |
| 9/30/2014 | 1,556 | 56 | N/A | N/A | N/A |
| 6/30/2014 | 1,425 | 26 | N/A | N/A | N/A |
| 3/31/2014 | 1,227 | -30 | N/A | 75 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MANGALAM's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if MANGALAM's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if MANGALAM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if MANGALAM's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if MANGALAM's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MANGALAM's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 23:29 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mangalam Drugs & Organics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vijay Madunala | FirstCall Research |